Joanne Grinch
Analyst at Citibank
Replay available
Glaukos Corporation (NYSE: GKOS) Q4 2025 earnings conference call, held 2026-02-17. Replay captured from the company's public earnings webcast.

Analyst at Citibank
Analyst at Truist
Analyst at Piper Sandler
Analyst at JPMorgan
Analyst at Wells Fargo
Analyst at BTIG
Analyst at William Blair
Analyst at Staple
Chairman and Chief Executive Officer
Analyst at Needham
Analyst at Stephens
President and Chief Operating Officer
Vice President of Investor Relations and Corporate Affairs
Chief Financial Officer
Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Gloucester's fourth quarter and full year 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, Simply press star, then the number one on your telephone keypad. I would now like to turn the call over to Chris Lewis, Vice President of Investor Relations and Corporate Affairs. Chris, please go ahead. Thank you and good afternoon. Joining me today are Galacos Chairman and CEO Tom Burns, President and COO Joe Gilliam, and CFO Alex Thurmond. Similar to prior quarters, the company has posted a document on its investor relations website under the financials and filings quarterly results section titled quarterly summary. This document is designed to be read by investors before the regularly scheduled quarterly conference call. To ensure ample time and opportunity to address everyone's questions, we request that you limit yourself to one question and one follow up. If you still have additional questions, you may get back into the queue. Please note that all statements other than statements of historical facts made on this call that address activities, events, or developments we expect, believe, or anticipate will or may occur in the future are forward-looking statements. These include statements about our plans, objectives, strategies, and prospects regarding, among other things, our sales, products, pipeline technologies and clinical trials, U.S. and international commercialization, market development efforts, product approvals, the efficacy of ...